Obermatt
See Similar Stocks →

NovoCure

NSQ:NVCR · JE00BYSS4X48
Health Care Equipment & SuppliesMedium

360

42
Profit price74
Owner Earnings Yield1
Dividend Yield1
Price/Sales29
EV / Gross Profit55
Price/Book5
Return on Capital13
Cash Return on Capital6
Return on Equity11
EBIT Margin10
Gross Profitability90
Accruals100
Owner Earnings Margin22
Sales growth39
Profit growth6
Reinvestment1
Price momentum53
Debt load37
Refinancing23
Debt Payback1
Liquidity25
Analyst ratings33
Opinion Changes50
Price Target Upside74
Market mood35
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

NovoCure doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryJersey
IndustryHealth Care Equipment & Supplies
SizeMedium
TypePublic Company
ExchangeNASDAQGS
Founded2000
Employees1,377
Websitenovocure.com
ISINJE00BYSS4X48
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Medical Equipment
Themes
Health DiagnosticsNeurologyOncologyBiomedical EngineeringHepatologyCentral Nervous System

Description

NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The company’s key pr…

Analysis

Middle-of-the-road

NovoCure Limited is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.

Valuation data is not available for this company.

The trajectory is moderate and the balance sheet is adequate. The company scores 2/20 on our value-creation score: not creating value.

Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250
4
2023202420252026

All-time high

9

Jan 2025

All-time low

1

Jan 2024

Average rank

5

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
29
27
46
3
Price/Earnings
95
4
4
4
Price/Book
5
11
28
12
Dividend Yield
1
1
1
1
Value (overall)
22
20
27
11

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare NovoCure with its peers
Kamada
NSQ:KMDA
82
CountryIsrael
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
RENK Group
GER:R3NK
37
CountryGermany
IndustryMachinery
SizeMedium
Full Stock Analysis →
Kiniksa Pharmaceuticals
NSQ:KNSA
99
CountryUK
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Anbio Biotechnology
NMQ:NNNN
—
CountryGermany
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
XCHG
NMQ:XCH
53
CountryGermany
IndustryElectrical Equipment
SizeSmall
Full Stock Analysis →
Embla Medical
CPH:EMBLA
61
CountryIceland
IndustryHealth Care Equipment & Supplies
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →